 
 
Clinimark  
[ADDRESS_713732]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713733] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   1   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
CLINIMARK Clinical Investigation Plan  
 
 SpO2 Accuracy Comparison of Smart Sock V. 2  SpO2 to Arterial Blood CO -
Oximetry  
PR 2017 -263 
 
COMMERCIAL SPONSOR:  
Owlet Baby [CONTACT_545492], Inc.   2500 Executive PKWY Suite 300 Lehi, UT [ZIP_CODE]  
 
Document 
Ownership:  Document is in accordance with Code of Federal Regulations for Non -Significant Risk Investigations and 
ISO [ZIP_CODE]  where applicable  
Function, Title  Name  [CONTACT_164300], Laboratory 
Manager  Roger Martin -
Pressman  
 30 NOV 2017  
 
Document  
Approver:  The document approvers are listed below:  
Function, Title  Name  [CONTACT_164300], Chief Clinical 
Officer  Paul Batchelder  
 30 NOV 2017  
Clinimark, Chief Technical 
Officer  Dena M. Raley  
 30 NOV 2017  
Owlet Baby [CONTACT_545492], Inc.  
Representative   
 
   
 
Revision 
History:  
Revision  Date  Revision Description  
Version 1  30NOV 2017  Original issue  
   
 
Author:   Roger Martin -Pressman  
  Laboratory Manager  
CLINIMARK, Laboratories  
Avista Adventist Hospi[INVESTIGATOR_164261]  
[ADDRESS_713734]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713735] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   2   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
SpO2 Accuracy Comparison of Smart Sock V. 2  SpO2 to Arterial Blood CO -
Oximetry  
PR 2017 -263 
ETHICS COMMITTEE REVIEW:  
Salus Institutional Review Board  
[ADDRESS_713736] Austin, TX [ZIP_CODE]  
John C. Lewis, DVM: Chairman Board 1  
Charles F. Ryan, PhD, RPh:  Vice -Chair Board 1  
Emory S. Martin, III, PharmD : Chairman Board 2   
Frederick N. Kopec, JD:  Vice -Chair Board 2  
Alexander Kenaston, RN, MS, PhD, CIP: Chairman Board 3  
Jennifer Christensen, PharmD, BCPS: Vice -Chair Board 3  
 
STUDY PROCEDURE:   
SpO2 Accuracy Comparison of Smart Sock V. 2  SpO2 to Arterial Blood CO -Oximetry  
Clinimark  Study ID# PR 2017 -263 
 
COMMERCIAL SPONSOR:  
Owlet Baby [CONTACT_545492], Inc.   2500 Executive PKWY Suite 300 Lehi, UT [ZIP_CODE]  
 
PRINCIPAL INVESTIGATOR:   
[INVESTIGATOR_136170] , MD.  
Avista Adventist Hospi[INVESTIGATOR_307], Staff Anesthesiologist  
[ADDRESS_713737]  
Louisville, CO [ZIP_CODE]  
 
SUB-INVESTIGATORS  
Paul Batchelder, LRCP, RRT   Dena Raley, BS Bio -Engineer  
Clinimark, Chief Clinical Officer   Clinimark, Chief Technical Officer  
 
Clinimark, LLC   
Business Address:  Pi[INVESTIGATOR_545482] , Golden, CO 8040 1 
 
MEDICAL OVERSIGHT:  
Arthur Cabrera, MD.  
Avista Adventist Hospi[INVESTIGATOR_307], Staff Anesthesiologist  
[ADDRESS_713738]  
Louisville, CO [ZIP_CODE]  
 
STUDY SITE:  
Clinimark Desaturation Laboratory,  Site ID# [ADDRESS_713739] 
Louisville, CO [ZIP_CODE]  
 
CONFIDENTIALITY:  
The information contained in this document is confidential and is intended for the use of clinical investigators.  It 
will not be copi[INVESTIGATOR_545483], Inc.  
unless such persons are bound by a confidentiality agreement with Clinimark or Owlet Baby [CONTACT_545492], Inc.  
 
 
Clinimark  
[ADDRESS_713740]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713741] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   3   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
SpO2 Accuracy Comparison of Smart Sock V. 2  SpO2 to Arterial Blood CO -
Oximetry  
PR 2017 -263 
 
Synopsis  
 
Introduction  
Owlet Baby [CONTACT_545492], Inc.  is a medical  device company focused on infant monitoring . The Owlet Baby [CONTACT_545492], Inc.  Smart 
Sock V. 2  device is a non-invasive home care device for use with infants .  The Smart Sock V. 2  is a portable device 
that uses pulse oximetry technology to enable oxygen saturation and heart rate monitoring in infants . 
 
Objectives of the Clinical Investigation Plan  
The purp ose of this clinical study  is to validate  the SpO 2 accuracy of Owlet Baby [CONTACT_545492], Inc.  Smart Sock V. 2 , during 
non-motion conditions over the range of 70 -100% SaO [ADDRESS_713742] 
separation of absorbencies of oxy -hemoglobin (O 2Hb) and deoxy -hemoglobin (RHb) states. The ratio of the two 
absorbencies is used to calculate the oxygen saturation (SpO 2) value. Because a n arterial sample of blood is not 
required to make the measurement, the pulse oximeter can provide continuous non -invasive real time 
information. The clinical use of pulse oximeters has reduced the frequency and necessity of invasive arterial blood 
samplin g, and has helped to improve patient safety by [CONTACT_545493]’ oxygenation status.  
  
The Smart Sock V. [ADDRESS_713743] safety testing has been previously completed.  
 
Summary Overview  
The SpO 2 accuracy performance of Smart Sock V. 2  will be evaluated during non -motion conditions over the range 
of 70 -100% SaO 2 and compared to a rterial blood samples assessed by [INVESTIGATOR_609] -Oximetry. A minimum of 10 healthy adult 
subjects, ranging in pi[INVESTIGATOR_545484], will be enrolled in the study to meet the study design 
requirements defined by [CONTACT_5891] [ZIP_CODE] -2-61:2011  and by [CONTACT_1622]’s Guidance for Pulse Oximeters (March 4, 2013). 
The subjects will have an arterial catheter placed in the radial artery to allow for simultaneous blood samples 
during stable plateaus of induced hypoxic levels. The investigational devices will be placed on both  thumbs  for the 
test sites . Simultaneous data collection will be set up for each of the systems under test.  This protocol will be 
focused on the Owlet Baby [CONTACT_545492], Inc.  Smart Sock V. 2 pulse oximeter intended to provide continuous oxygen 
saturation measurement of humans.  
 
For analysis  of the data;  the control oximeter will be used to assess the stability of each data point. Data that is 
found to be unstable will be removed prior to the comparative analysis. The CO -Oximeter data will be reviewed to 
 
 
Clinimark  
[ADDRESS_713744]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713745] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   4   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
make sure it does not contain any anomalous values such as elevated, low or inconsistent  COHb, MetHb , tHb  data. 
Anomalous values will be removed from the analysis prior to pairing of the SpO [ADDRESS_713746] 10 subjects for the range of 7 0% to 
100% SaO 2 with allowance of ± 3% of the target range . Functional SaO 2 as measured by [CONTACT_136179] -Oximetry will 
be used as the basis for comparison. The Accuracy Root Mean Squar e (A RMS) calculation is used to determine the 
SpO [ADDRESS_713747] Reference CO -Oximetry providing documentation to support SpO 2 accuracy claims for the inv estigational 
device (s). 
 
Subject enrollment and participation in this clinical study is based on meeting the inclusion criteria and none of the 
exclusion criteria, a satisfactory health screen, and the subject and data demographics needed for the study.   This 
inclusion/exclusion criteria  listed below  is to ensure patient safety in the hypoxia procedure and is unrelated to the 
Smart Sock V. 2  device . 
 
Inclusion Criteria  
• 10-15 Adults with a minimum of 3 males and a minimum of 3 females, with the balance made up of 
either.  
• Subject must have the ability to understand and provide written informed consent  
• Subject is 18 to 50 years of age  
• At least 2 darkly pi[INVESTIGATOR_545485] 15% of the s ubject pool, whichever is larger  
• Subject must be willing and able to comply with study procedures and duration  
• Subject is a non -smoker or who has not smoked within 2 days prior to the study.  
 
Exclusion Criteria  
• Subject is considered as being morbidly obese (defined as BMI >39.5)  
• Compromised circulation, injury, or physical malformation  of fingers, toes, hands, ears or forehead/skull 
or other sensor sites which would limit the ability to test sites needed for the study.  (Note: Certain 
malformations may still allow subjects to participate if the condition is noted and would not affect the 
particular sites utilized.)  
• Females who are pregnant, who are trying to get pregnant, or have a urine test positive for pregnancy on 
the day of the study   
• Smoker Subjects who have refrained will be screened for COHb levels . >3% as assessed with a Masimo 
Radical 7 (Rainbow)  
• Subjects with known respi[INVESTIGATOR_136172]: (self -reported)  
o uncontrolled / severe asthma,  
o flu,  
o pneumonia / bronchitis,  
o shortness of breath / respi[INVESTIGATOR_1506],  
o respi[INVESTIGATOR_545486],  
o emphysema, COPD, lung disease  
• Subjects with known heart or cardiovascular conditions such as: (self -reported, except for blood pressure 
and ECG review)  
o hypertension: systolic >140mmHg, Diastolic >90mmHg on 3 consecutive readings (reviewed during 
health screen).  
o have had cardiovascular surgery  
o Chest pain (angina)  
o heart rhythms other than a normal sinus rhythm or with respi[INVESTIGATOR_25570] (reviewed 
during health screen)  
o previous heart attack  
 
 
Clinimark  
[ADDRESS_713748]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713749] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   5   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
o blocked artery  
o unexplained shortness of breath  
o congestive heart failure (C HF) 
o history of stroke  
o transient ischemic attack  
o carotid artery disease  
o myocardial ischemia  
o myocardial infarction  
o cardiomyopathy  
• Self-reported health conditions as identified in the Health Assessment Form (self -reported)  
o diabetes,  
o uncontrolled thyroid dise ase,  
o kidney disease / chronic renal impairment,  
o history of seizures (except childhood febrile seizures),  
o epi[INVESTIGATOR_002],  
o history of unexplained syncope,  
o recent history of frequent migraine headaches,  
o recent symptomatic head injury within the last 2 months  
o cancer / chemotherapy  
•  Subjects with known clotting disorders (self -reported)  
o history of bleeding disorders or personal history of prolonged bleeding from injury  
o history of blood clots  
o hemophilia  
o current use of blood thinner s such as  prescription or daily use of aspi[INVESTIGATOR_248]  
• Subjects with severe contact [CONTACT_136184], latex or other materials found in pulse 
oximetry sensors, ECG electrodes, respi[INVESTIGATOR_136174] (self -
reported)  
• Subjects w ith severe  allergies to iodine  
• Subjects with severe  allergies to  lidocaine (or similar pharmacological agents, e.g. Novocaine)  
• Failure of the Perfusion Index Ulnar/Ulnar+Radial Ratio test  
• Unwillingness or inability to remove colored nail polish from test digits.  
• Other known health condition, should be considered upon disclosure in health assessment form  
 
Data collection will occur over a  3-[ADDRESS_713750]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713751] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   6   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Table of Contents  
Synopsis  ................................ ................................ ................................ ................................ ................................ .........  [ADDRESS_713752]  ................................ ................................ ................................ .........................  11 
Arterial Syringes  ................................ ................................ ................................ ................................ ...................  11 
Reference CO -Oximeters  ................................ ................................ ................................ ................................ ..... 11 
Preliminary Investigations and Justifications of the Study  ................................ ................................ ......................  11 
Risks and Benefits of the Investigational Device and Clinical Investigation  ................................ ................................  11 
Invasive Laboratory Testing on Healthy Volunteers  ................................ ................................ ................................  12 
Controlled Desaturation Study  ................................ ................................ ................................ ................................  12 
Radial Arterial Line  ................................ ................................ ................................ ................................ ...................  12 
Lidocaine  ................................ ................................ ................................ ................................ ................................ .. 13 
Pulse Oximetry Sensor  ................................ ................................ ................................ ................................ .............  13 
ECG Electrodes  ................................ ................................ ................................ ................................ .........................  13 
Ultrasound  ................................ ................................ ................................ ................................ ...............................  13 
Blood Pressure Cuff  ................................ ................................ ................................ ................................ .................  13 
Heating Pad / Hot Water Bottles  ................................ ................................ ................................ .............................  14 
Perfusion Index Ulnar/Ulnar+Radial Ratio test  ................................ ................................ ................................ ........  14 
Benefits  ................................ ................................ ................................ ................................ ................................ .... 14 
Design of the Clinical Investigation  ................................ ................................ ................................ ..............................  14 
Method  ................................ ................................ ................................ ................................ ................................ .... 14 
Endpoint / Comparator  ................................ ................................ ................................ ................................ ............  [ADDRESS_713753]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713754] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   7   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Exclusion Criteria  ................................ ................................ ................................ .... Error! Bookmark not defined.  
Duration of Clinical Investigation ................................ ................................ ................................ .............................  17 
Criteria for Study Termination  ................................ ................................ ................................ ................................ . 17 
Procedure  ................................ ................................ ................................ ................................ ................................ .... 17 
Statistical Analysis ................................ ................................ ................................ ................................ ....................  19 
Control oximeter stability criteria ................................ ................................ ................................ ........................  20 
CO-Oximeter Data  ................................ ................................ ................................ ................................ ...............  20 
Pass / Fail Criteria  ................................ ................................ ................................ ................................ ................  [ADDRESS_713755] (IRB)/Independent Ethics Comm ittee (IEC)  ................................ ................................ .. 21 
Monitoring Arrangements  ................................ ................................ ................................ ................................ .......  22 
Monitoring Plan  ................................ ................................ ................................ ................................ .......................  22 
Data and Quality Management / Confidentiality  ................................ ................................ ................................ .... 22 
Records - Study Documentation / Case Report Forms  ................................ ................................ ............................  [ADDRESS_713756] Documents  ................................ ................................ ................................ ................................ ..................  23 
Data Colle ction Forms / Case Report Forms  ................................ ................................ ................................ ............  [ADDRESS_713757]  ................................ ................................ ................................ ................................ ................................ . 26 
Adverse Event Definitions ................................ ................................ ................................ ................................ .... 27 
Management of Adverse Event Reporting  ................................ ................................ ................................ ..............  27 
Reporting of Serious Adverse Events and / or UADE  ................................ ................................ ...............................  27 
Sponsor Records and Reports  ................................ ................................ ................................ ................................ .. 28 
Records 21 CFR 812.140 (b) 4,5  ................................ ................................ ................................ ...........................  28 
Reporting 21 CFR 812.150 (b) 1,2,3,5,6,7,8,9,10:  ................................ ................................ ................................  [ADDRESS_713758]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713759] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   8   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Withdrawal if FDA approval  ................................ ................................ ................................ ................................ . 28 
Progress Reports  ................................ ................................ ................................ ................................ ..................  28 
Recall and device  ................................ ................................ ................................ ................................ .................  28 
Final Report  ................................ ................................ ................................ ................................ .........................  28 
Informed consent  ................................ ................................ ................................ ................................ ................  28 
Significant risk device determinations – (does not apply to NSR studies)  ................................ ...........................  28 
Other  ................................ ................................ ................................ ................................ ................................ .... 29 
Investigators Records and Reporting  ................................ ................................ ................................ .......................  29 
Records 21 CFR 812.140 (a)(3)(i)  ................................ ................................ ................................ .........................  29 
Reports 21 CFR 812.150 (a) 1,2,5,[ADDRESS_713760]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713761] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   9   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
SpO2 Accuracy Comparison of Smart Sock V. 2  SpO2 to Arterial Blood CO -
Oximetry  
PR 2017 -263 
 
Objectives of the Clinical Investigation Plan  
The purp ose of this clinical study  is to evaluate the SpO 2 accuracy performance of the Owlet Baby [CONTACT_545492], Inc.  Smart 
Sock V. 2  during non -motion conditions over the range of 70 -100% SaO 2 as compared to arterial blood samples 
assessed by [INVESTIGATOR_609] -Oximetry .  The end goal is to provide supporting doc umentation for the SpO 2 accuracy validation 
of the  Owlet Baby [CONTACT_545492], Inc.  Smart Sock V. 2 . 
 
It is required  that the Accuracy Root Mean Square (A RMS) performance of the Owlet Baby [CONTACT_545492], Inc.  Smart Sock V. 2  
SpO 2 will meet a specification of 3 or better in no n-motion conditions for the range of 70 – 100% SaO 2 thereby 
[CONTACT_98833] 2 accuracy performance specification.  
 
Identification and Description of the Investigational Device  
An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the 
blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is 
considered a standard physiological measurement and is used by [CONTACT_545494]. Because an arterial sample of blood is not required to make the measurement, the 
pulse oximeter can provide non -invasive real time information. The clinical use of pulse oximeters has reduced the 
frequency and ne cessity of invasive arterial blood sampling, and has helped to improve patient safety by [CONTACT_545495]’ oxygenation status.  
  
The device used in this investigational study is the Owlet Baby [CONTACT_545492], Inc.  Smart S ock V. [ADDRESS_713762] that measures a baby’s oxygen levels and  
heart rate via a sensor embedded in a sock (smart sock). The monitor comprises a wireless  pulse oximeter sensor 
that sends the acquired information to a base station within the  baby's roo m. The base station optionally relays 
the information to the caretaker’s  smartphone for display of pulse rate and blood oxygen levels via the Owlet Baby 
[CONTACT_545492], Inc.  app.  
 

 
 
Clinimark  
[ADDRESS_713763]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713764] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   10   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
         
 
This protocol will be focused on the Owlet Baby [CONTACT_545492], Inc.  Smart Sock V. 2 pulse oximeter intended to provide 
continuous oxygen saturation measurement of humans  
 
All appropriate testing to demonstrate safety for use in human studies prior to Clinimark’s receipt of the device  
was completed . Such documentation will reside in the design history files of the Sponsor. Documentation will be 
provided regarding the safety of the investigational device for patient leakage, dielectric strength, surface 
temperatures and biocompatibility testing . In this study only the Smart Sock V. [ADDRESS_713765] or production equivalent builds.  
 
Instruction s for installation, use, storage and handling can be found the Device Operator’s Manual and or 
Instructions for Use. Device model numbers, software version, serial numbers, date(s) of use, subject ID number(s) 
will be recorded in the study documentation.   
 
The Clinimark staff is familiar with the use of pulse oximet ers and the ir application . Training by [CONTACT_545496]. The data collection for the investigational devices will be performed by a representative from 
the Sponsor or by a trained member of Clinimark.   
 
Data Acquisition System for the I nvestigational Device  
The data from the investigational devices will be collected to a computer separate from the reference Control 
Oximeter and in parallel sent to the Cl inimark automated data collection system.   
 
Desaturation Study Gas Delivery System  
The Clinimark proprietary Desaturation Fixture with Automated Data Collection is a single limb blow by [CONTACT_136182] 
a slow steady rate allowing an automatic marking and collection of the Control or secondary Transfer 
reference Pulse Oximeter and other pulse oximetry systems at 1 second intervals.  
Description of Clinimark D esaturation Fixture with Automated Data Collection:  
• Computer with desaturation gas control software and automated data collection system  
• Sealink Mux box – 8 channel, communication cables  
• Gas control fixture  
• Medical grade oxygen and nitrogen cylinders   
 
Control Oximetry System  
The Control Pulse Oximeter, an FDA cleared device, is used to monitor the oxygen saturation levels real time 
throughout the study for subject safety and to target stable plateaus. This device is used to assess the stability 
of the da ta.  
• GE Healthcare (Datex -Ohmeda) 3900 TruTrak+ / OxyTip+ Oxy -F-UN or Oxy -AF Sensor and Oxy -OL3 cable  

 
 
Clinimark  
[ADDRESS_713766]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713767] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   11   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
• Covidien Nellcor N -600x with MaxFast  Forehead sensor and DOC -[ADDRESS_713768]’s vital signs including ECG tracing, heart 
rate, respi[INVESTIGATOR_697], end -tidal CO [ADDRESS_713769]. This device will also serve as the pulse rate reference.  
• GE Healthcare S5 Compact Monitor, M -NESTPR module with ECG  
• Portable oxygen tank, mask and ambu bag  
• Blood pr essure cuff and stethoscope  
 
Breathing Apparatus for Subject  
The breathing apparatus sits over the subject’s nose and mouth and is held in place by a four -tailed head strap 
and connected to a gas mixer and O 2 analyzer as well as the patient monitor.  The breathing apparatus 
consists of the following (or similar) components.  
• air cushion breathing mask with hook ring  
• gas sampling adapter  
• tee connector  
• CO 2 sampling line: connected to the patient monitor for respi[INVESTIGATOR_697], ETCO 2 and capnograph.  
 
Arterial Sy ringes  
Arterial Blood Sample Syringe with Dry Lithium Heparin for Gases and Electrolytes  
• Portex 3ml Pro -Vent  
  
Reference CO -Oximeters  
A whole blood analyzer (CO -Oximeter) is used as the reference standard device for obtaining the functional 
SaO 2 value from arterial blood samples obtained during the study.  
• Radiometer ABL 80 Flex OSM and associated supplies ID#: 302125, 306173, 307205 , 313093, 313102  or 
equivalent  (utilizing Radiometer and / or IL682 calibration)  
• And / or other reference CO -Oximeter (optional)  
 
Preliminary Investigations and Justifications of the Study  
As part of the product development and validation phase s for the  Owlet Baby [CONTACT_545492], Inc.  Smart Sock  V. 2, studies 
were  conducted at Shenzen Laboratories in [ADDRESS_713770]  and a Radiometer OSM 3 hemoximeter  to evaluate  the SpO 2 
accuracy of  the Owlet Baby [CONTACT_545492], Inc.  Smart Sock V. 2 .   
 
In review of the literature, the FDA Guidance Document for Pulse Oximeters and ISO [ZIP_CODE] -2-61 clearly define the 
accepted guideline for evaluation and documenting the SpO 2 accuracy in humans.  
 
See Section: Reference Doc uments, below.  
 
Risks and Benefits of the Investigational De vice and Clinical Investigation  
Currently the FDA defines pulse oximeters as Class II devices which transmit radiation at a known wavelength(s) 
through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered 
radiation and may be used alone or in con junction with a fiberoptic oximeter catheter. All oximeters being used in 
this study work by [CONTACT_545497](s) through tissue to measure blood oxygen 
saturation based on the amount of reflected and scattered radiation. The d evices under test and this study 
procedure  are considered Non-Significant Risk (NSR) .  
 
 
Clinimark  
[ADDRESS_713771]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713772] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   12   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
 
The device and use of the device under test does not meet the definition of significant risk device under 21 CFR 
812.3(m)  
 
For the purpose of this study:  
• It is not int ended as an implant.  
o Pulse oximetry sensors are applied to the surface of the site (su ch as forehead, ears, and fingers ) and 
are removed following data collection , less than 1 day.   
o Sensors may be warm to the touch but are not expected to overheat during normal operations  
o The pulse oximetry systems along with the other finger clip sensors, reusable sensors , and the 
forehead headband which may exert a small amount of pressure with mild discomfort  
o Adhesives may cause some skin irritations.  
• It is not purported or represented to be for use in supporting or sustaining human life, nor does it present a 
potential for serious risk to the health, safety, or welfare of a subject.  
o Pulse oximeters are monit ors and are not used to support or sustain human life.  
• It is not for use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise 
preventing impairment of human health  
o Pulse oximeters are Class II devices used to mea sure the blood oxygen saturation.  They are not used 
to diagnose, cure mitigate or treat disease. These devices are typi[INVESTIGATOR_348535] a general 
indication for non -invasive measurement of blood oxygen saturation.  
• The device as used in this investigatio n does not present a serious risk to the health, safety, or welfare of a 
subject.  
o See below for discussion of risk associated with the device and use of the device.  
 
Invasive Laboratory Testing on Healthy Volunteers  
The risk determination is based on the u se of the device in an investigation in addition to the device itself. 
Generally, the FDA believes pulse oximeters as addressed in the FDA Guidance Document for Pulse Oximeters 
(March 4, 2013) are non -significant risk devices. Further, the recommendation i s to conduct the study in 
accordance with Clause [IP_ADDRESS].2 and Annex EE.2 of ISO [ZIP_CODE] -2-61:2011, where Annex EE.2 describes the 
procedure for invasive laboratory testing on healthy volunteers.  
 
Controlled Desaturation Study  
Desaturation of the subjec t involves the administration of oxygen/nitrogen mixtures that are less than that of 
normal air, i.e., less than 21% oxygen.   The minimum percentage of oxygen to be delivered is 9% which results in 
blood oxygen saturation levels similar to those that are seen in healthy individuals who are at a 14,000 to 17,000 
feet elevation.  Potential symptoms include air hunger, dizziness, faster breathing, higher pulse rate, and tingling in 
the hands or feet or loss of consciousness. Vision changes such as ‘starring’ or ‘tunnel vision’ can also occur.  In the 
event of any of the above symptoms the subject can be returned to room air or given high levels of oxygen.  All of 
these symptoms, if they occur, reverse within minutes of discontinuation of the testing.  During t he test, the subject 
is closely monitored and constant communication regarding the subjects comfort and sense of well -being is 
assessed. The ECG, pulse oximetry saturation, inspi[INVESTIGATOR_545487], and exhaled carbon dioxide are 
monitored.  Since [ADDRESS_713773]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713774] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   13   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
discomfort.  The total amount of blood drawn during the procedur e is less than 150cc.  The possible risks from the 
arterial catheter include: pain, hyperventilation, pressure, muscle/artery spasm, fracture of the catheter under the 
skin (which may require an additional procedure for catheter retrieval)  with insertion; discomfort with saline flush 
(cool, burning, or tingling sensation distal to the arterial line site, especially in the finger tips), or pain, hematoma 
(bruising), clotting, and scar formation.  All precautions to minimize discomfort will be taken, includin g a small 
injection of Lidocaine (a numbing medicine) under the skin at the insertion site.  A vascular assessment will be 
conducted prior to cannulation of the artery to verify the presence of adequate collateral blood flow to the hand.  
The risk of radia l arterial catheterization is believed to be minimal.   
 
Lidocaine  
The risks associated with use of Lidocaine as a numbing medicine may include discomfort or pain (burning or 
stinging) with injection; allergic reaction to medication; transient numbness in finger(s) . 
 
Pulse Oximetry Sensor  
Pulse Oximetry Sensor placement involves positioning pulse oximetry sensors on the volunteer subject in the same 
manner that is used on hospi[INVESTIGATOR_9643].  For the purposes of this study; the Smart Sock V. 2 will be placed on 
the thumbs of the adult population.  The sensors may be warm to the touch. Under normal operating conditions, 
(no fault conditions), the sensors are not expected to overheat. If the sensors are too warm, they will be removed 
immediately .  Clip on and soft reusable sensors exert a minimal amount of pressure. They should not cause 
discomfort. Sensor retention headband for the forehead sensor exert a minimal amount of pressure and may 
cause a headache if on for extended periods of time. If the sensors are too uncomfortable, they will be removed 
immediately.  Adhesive sensors or tape may cause some irritations to the skin in some subjects. Every effort will be 
made to minimize products with natural rubber or latex. Products containing natural  rubber or latex will be 
identified.  The risk in the use of pulse oximetry sensors is believed to be minimal . 
 
ECG Electrodes  
Materials (such as the adhesive and/or gel contact) used in the electrodes may cause some skin irritations in some 
subjects. Typ ical skin irritations present with redness of skin and in some cases of sensitivity is an allergic reaction. 
Because the adhesive is aggressive on the ECG pads, it may cause pulling of the skin or hair upon removal. 
Biocompatibility testing for surface con tact electrodes is a requirement of the International Standards Organization 
(ISO) [ZIP_CODE] – Biological Evaluation of Medical Devices. The risk in the use of ECG electrodes is believed to be 
minimal.  
 
Ultrasound  
Ultrasound utilizes high frequency sound waves  to produce images of internal body structures. There are no 
anticipated risks.  The ultrasound will be used to detect the radial artery in screening and assist in placement of the 
arterial catheter before data collection.  The placement of the arterial li ne will be performed under sterile 
conditions.  Ultrasound gel  will not be used on subjects with known allergies .   
 
Blood Pressure Cuff  
The reported risks associated with NIBP include A) slight discomfort upon inflation of the cuff, B) possible bruising, 
C) petechial rash and D) discoloration of the skin beneath the cuff. In rare instances the reported risks associated 
with NIBP include A) peripheral nerve injuries B) skin tear, and C) compartment syndrome (swelling of muscles in 
the limb causing  the reduction of the blood supply to the muscle).  
 
More than 3,[ADDRESS_713775] had their blood pressures taken repeatedly in 104 
studies using similar equipment.  In these previous studies, the complications of taking repeate d blood pressures 
were temporary and involved either bruising/rash; for example, petechiae rash (less than 2.2%), skin redness/lines 
(0.8%), or tingling/discoloration in the extremity wearing the cuff while the cuff is inflated (0.1%).  
 
 
 
Clinimark  
[ADDRESS_713776]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713777] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   14   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
It is possible that  the test subject may experience an allergic reaction to the material in the cuff.  However, cuffs 
used in this trial for screening utilize standard material that has undergone skin sensitivity testing.   
 
 
Heating Pad / Hot Water Bottles  
A heating pad or hot water bottles may be used on the arm to improve the circulation to the finger site. Mild 
discomfort can be expected if it is too warm. To minimize the discomfort, the subject will be asked about comfort 
level. If the heating is too warm, it will be tur ned on the lowest level possible, removed or additional separation 
will be used between the heater and the site for comfort.  
 
Perfusion Index Ulnar/Ulnar+Radial Ratio test  
During the Perfusion Index Ulnar/Ulnar+Radial Ratio test for assessment of sufficie nt collateral circulation, the 
wrist is squeezed for less than 1 minute. This may cause minimal discomfort.  
 
There are no anticipated risks or adverse device effects to be assessed. There are no contraindications for use in 
the proposed study / study popu lation. There may be other risks to the subject associated with the device or 
procedure that are unforeseeable at this time.  
 
Benefits  
The benefits to the study are to the advancement of non -invasive medical devices  by [CONTACT_545498] (SDB) devices . There are no direct benefits to the 
subjects participating in this study  other than being a paid volunteer. The only alternative to this study is to NOT 
participate.  
 
Design of the Clinical Investigation  
 
Method  
This study is a comparative, single -center, non -randomized study in  up to [ADDRESS_713778]  set will occur over a 3 -5 day period.  
 
Subjects will be provided an IRB approve d Informed Consent which covers the essential information in the 
protocol, ISO [ZIP_CODE]  (as reference only)  and applicable regulatory requirements for a non -significant risk medical 
device investigation. Subjects will be provided sufficient time to review the informed consent and have all 
questions answered regarding their participation before enrollment or con duct of study specific procedures. As 
applicable, subjects will be told about any new information that might change their decision to participate.  
 
Subjects who have completed (signed and dated) the informed consent and health questionnaire form, and meet  
inclusion criteria and none of the exclusion criteria will be enrolled in the study. If the Informed Consent Form (ICF) 
is amended/updated throughout the life -cycle of the study, a determination will be made as to whether the 
subjects who have completed t he study need to re -consent by [CONTACT_42574], signing and personally dating the 
updated ICF.  
 
Qualified healthy volunteers will be enrolled into the study. Subjects will recline for the study. A Control Pulse 
Oximetry sensor will be placed on each subject to monitor the real time SpO [ADDRESS_713779] devices will be evaluated over the oxygen saturation range between 70 -100%.   
 
 
Clinimark  
[ADDRESS_713780]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713781] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   15   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
 
Endpoint / Comparator  
The primary objective of this study is to validate  SpO 2 accuracy performance of the Owlet Baby [CONTACT_545492], Inc.  Smart 
Sock V. 2  by [CONTACT_545499] ( Arms) value.  Reference CO -Oximetry, will be used as the basis for 
comparison for the investigational device SpO [ADDRESS_713782] approximately 200 data points equally distributed across the range of 70 -100% by 
[CONTACT_125938]. All data will be used for the analysis unless a rational is provided for its removal. Possible reasons for data 
removal include , but are not limited to, unstable control, dashed or z ero values, poor perfusion at the site, 
inconsistent or invalid CO -Oximetry  values.  Data that is found to not be  useable will be removed prior to the 
comparative analysis. For the statistical analysis, the Accuracy Root Mean Square (A RMS) calculation is us ed to 
determine the SpO [ADDRESS_713783] operating procedures . 
 
Study Population  
The study population  per set  will include 10 to 15 healthy non -smoking (or has refrained from smoking for 2 days) 
competent adults, ages [ADDRESS_713784] 2 darkly pi[INVESTIGATOR_545485] 15% of the subject pool, 
whichever is larger.  
 
The subjects must understand the study and consent to participate by [CONTACT_246629]. The 
subjects must be healthy showing no evidence of medical problems as indicated by [CONTACT_545500].  
   
Subject enrollment is based on meeting the inclusion criteria and none of the exclusion criteria, a satisfactory 
health screen, and the subject and data demographics needed for the study.  This inclusion/exclusion criteria listed 
below is to ensure patient safety in the hypoxia procedure and is unrelated to Smart Sock V. 2  device.  
 
Inclusion Criteria  
• 10-15 Adults with a minimum of 3 males and a minimum of 3 females, with the balance m ade up of 
either.   
• Subject must have the ability to understand and provide written informed consent  
• Subject is 18 to 5 0 years of age  
• At least 2 darkly pi[INVESTIGATOR_545485] 15% of the subject pool, whichever is larger  
• Subject must be willing and able to comply with study procedures and duration  
• Subject is a non -smoker or who has not smoked within 2 days prior to the study.  
 
Exclusion Criteria  
• Subject is considered as bein g morbidly obese (defined as BMI >39.5)  
• Compromised circulation, injury, or physical malformation  of fingers, toes, hands, ears or forehead/skull 
or other sensor sites which would limit the ability to test sites needed for the study.  (Note: Certain 
malfor mations may still allow subjects to participate if the condition is noted and would not affect the 
particular sites utilized.)  
• Females who are pregnant, who are trying to get pregnant, or have a urine test positive for pregnancy on 
the day of the study   
• Smoker Subjects who have refrained will be screened for COHb levels . >3% as assessed with a Masimo 
Radical 7 (Rainbow)  
 
 
Clinimark  
[ADDRESS_713785]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713786] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   16   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
• Subjects with known respi[INVESTIGATOR_136172]: (self -reported)  
o uncontrolled / severe asthma,  
o flu,  
o pneumonia / bronchitis,  
o shortn ess of breath / respi[INVESTIGATOR_1506],  
o respi[INVESTIGATOR_545486],  
o emphysema, COPD, lung disease  
• Subjects with known heart or cardiovascular conditions such as: (self -reported, except for blood pressure 
and ECG review)  
o hypertension: systolic >140mmHg, Diastolic >90mmHg on 3 consecutive readings (reviewed during 
health screen).  
o have had cardiovascular surgery  
o Chest pain (angina)  
o heart rhythms other than a normal sinus rhythm or with respi[INVESTIGATOR_25570] (reviewed 
during health screen)  
o previous heart attack  
o blocked artery  
o unexplained shortness of breath  
o congestive heart failure (CHF)  
o history of stroke  
o transient ischemic attack  
o carotid artery disease  
o myocardial ischemia  
o myocardial infarction  
o cardiomyopathy  
• Self-reported health conditions as identified in the Health Assessment Form (self -reported)  
o diabetes,  
o uncontrolled thyroid disease,  
o kidney disease / chronic renal impairment,  
o history of seizures (except childhood febrile seizures),  
o epi[INVESTIGATOR_002],  
o history of unexplained syncope,  
o recent h istory of frequent migraine headaches,  
o recent symptomatic head injury within the last 2 months  
o cancer / chemotherapy  
•  Subjects with known clotting disorders (self -reported)  
o history of bleeding disorders or personal history of prolonged bleeding from injury  
o history of blood clots  
o hemophilia  
o current use of blood thinner s such as  prescription or daily use of aspi[INVESTIGATOR_248]  
• Subjects with severe contact [CONTACT_136184], latex or other materials found in pulse 
oximetry sensors, ECG electrodes, resp iration monitor electrodes or other medical sensors (self -
reported)  
• Subjects with severe  allergies to iodine  
• Subjects with severe  allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine)  
• Failure of the Perfusion Index Ulnar/Ulnar+Radial Ratio test  
• Unwillingness or inability to remove colored nail polish from test digits.  
• Other known health condition, should be considered upon disclosure in health assessment form  
 
 
 
 
Clinimark  
[ADDRESS_713787]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713788] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   17   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Duration of Clinical Investigation  
Each subject, and therefore use of the d evice, is expected to take 1.5-2 hours. Data collection will occur over a 3 -5 
day period for this study population.   
 
Criteria for Study Termination  
The study will be terminated if any of the following conditions occurs:  
• The subject may stop the study for any reason without prejudice  
• The clinician or gas controller may terminate the study at his/her discretion  
• Unable to obtain vascular access  
• Initial blood draw values of, COHb >3%, MetHb > 2%, and tHb <10g/dl   
• Development of any cardiac arrhythmia, exc ept sinus arrhythmia <120 bpm  
• Development of clinically significant ST or T segment changes in the ECG  
• Sustained sinus tachycardia ≥120 bpm  
• Onset of PVCs  
• The lowest target is 7 0% SpO 2. Due to unpredictable human physiology, the subject may drift below 67%. 
Should this occur, an attempt will be made to increase the oxygen saturation level by [CONTACT_545501] 2 level 
to achieve a SpO 2 in the 67-73% range or a decision is made to increas e the FiO [ADDRESS_713789] prior to starting study. Calibrate / check FiO 2 monitor(s).    
2. Set the  clocks to sync data collection between the Sponsor and Clinimark systems.  
3. Explain the procedure to the subject. Have them read the Informed Consent Form, and review the information 
answering all questions. Once all questions have been answered, have the subject sign the form. Have the 
subject complete the Health Assessment Form and verbally question the subject about their health history. 
Each subject will be asked if they want a copy of the consent form prior to release. Female subjects will take a 
urine pregnancy test.  
4. Apply Finger sensor to thumb where the arterial line placem ent is intended.  Record perfusion index (PI) value 
from 3900 TT+ Pulse Oximeter. Perform a modified Allen’s test to ensure sufficient blood flow to the hands. 
Occlude both radial and ulnar arteries until there is no plethysmographic waveform and the PI [INVESTIGATOR_545488]. Release the ulnar artery holding the radial artery firm. Record the PI [INVESTIGATOR_67147]. The ratio of the ulnar artery PI 
[INVESTIGATOR_545489] 0.[ADDRESS_713790]’s blood pressure and record values.  
6. Apply ECG leads to the subject, review for normal sinus rhythm.  
7. Based on the responses to the  Health assessment form, record accepted or declined from the study. Continue 
if accepted into the study.  
8. A qualified clinician will use local anesthesia and then place the arterial catheter in the radial artery of the 
non-dominate hand (preferred). The ar terial line is then secured with tape to the subject’s arm.  
9. Setup and verify communication between the devices and data collection system.  
10. Record device information for tracking. (manufacturer, model #, serial or lot, hardware / software control 
info).  
11. Record subject information. Subject number and demographics information for subject description.  
12. Have subjects recline.  
 
 
Clinimark  
[ADDRESS_713791]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713792] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   18   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
13. Apply sensors to the subject. Shield any adjacent sensors to prevent optical cross -talk.  The sponsor may take 
photographs to document sen sor placement.  
14. Adjust sensors as appropriate and record on test form.  
15. A hot water bottle may be placed on each arm to improve the perfusion and facilitate the blood draws.  
16. Allow readings to stabilize. Record baseline SpO [ADDRESS_713793] form.  
17. Begin program to start gas flow. Verify that FiO 2 is at appropriate starting level (typi[INVESTIGATOR_897] 18 -21%) prior to 
connecting subject to breathing circuit.  
18. Connect the subject to the breathing circuit and adjust the gas flow delivery for subject comfort.  
19. Start data collection.  
20. The program will be run in manual mode. Gas mixture changes will be set by [CONTACT_545502]. The gas mixture 
will be delivered to induce hypoxia in a stair stepped manner.  Data collection will be evenly distributed by 
[CONTACT_545503].   
21. The clinician monitors and records the following information periodically. SpO 2, pulse rate, EtCO 2, respi[INVESTIGATOR_11943], relevant information on the ECG rhythm, FiO 2. The clinician will monitor the arterial line and subject’s 
well-being throughout the test confirming that the subject is doing “ok”. Subject will be advised during the 
study that he/she may stop the test at any time.  
22. While breathing room  air, collect baseline arterial samples and measure on the CO -Oximeter. The method for 
sampling will be:  
• Mark data for start of stability period hold ~30 seconds to 1 minute  
• Draw waste or leader blood sample prior to draw, mark data  
• Draw arterial blood sam ple marking data  
• Wait ~15 to 30 seconds, draw waste or leader blood sample prior to draw  
• Draw additional arterial blood sample marking data  
• If a closed arterial blood collection system is used then the leader blood will be returned. Flush the 
line with ste rile saline.  
• Change to next gas level  
Note timing may vary based on the subject’s stability.  
23. Should the initial COHb reading be out of range (>3%) as measured by [CONTACT_136179] -Oximetry, then a 
determination will be made as to the viability of blowing off th e COHb levels through an exercise of 
hyperventilation and elevated levels of oxygen being administered to the subject. If this is the case, blood 
samples will be drawn to monitor the COHb level until it is acceptable or a determination is made to withdraw 
the subject.  
24. Multiple plateaus will be achieved throughout the range from 100% to 70%.  
25. The clinician monitors and records the following information periodically. SpO 2, pulse rate, EtCO 2, respi[INVESTIGATOR_11943], relevant information on the ECG rhythm, FiO 2. The c linician will monitor the subject’s wellbeing  
throughout  the test confirming that the subject is doing ok.  
26. Subject will be advised during the study that he/she may stop the test at any time.  
27. The gas controller monitors the gas delivery and data collection  system to ensure proper functionality. 
Performance of the test devices may be noted on the form as well.  
28. The test may be stopped at any time by [CONTACT_423], the clinician, the gas controller. The test will also be 
stopped if the SpO 2 level goes below the minimum SpO 2 or the FiO 2 goes below 9%.  
29. Arterial blood sampling will be repeated at each stable plateau. Method used will be same as described in step 
#[ADDRESS_713794]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713795] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   19   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
 
Goal is to collect 20 – [ADDRESS_713796] will be 
given a gas mixture returning him/her to baseline levels.  
31. The subject may be re -saturated to above 80% SpO [ADDRESS_713797] is monitored for a few minutes to ensure he/she 
maintains normal baseline levels.  
33. All equipment will be removed  from the subject.  
34. The arterial line will be removed and a pressure bandage will be applied to the subject for approximately [ADDRESS_713798] the study.  
 
Statistical Analysis  
This study is intended to validate  SpO 2 accuracy c laims  of the Owlet Baby [CONTACT_545492], Inc.  Smart Sock V. 2  SpO 2 Sensor 
during non-motion conditions over the range of 70 -100% SpO 2 in comparison to a Reference CO-Oximeter. Data 
analysis may  occur in the following manner:  
 
Data analysis will follow ISO80601 -2-61, Annex EE and the FDA Guidance Document for Pulse Oximeters (March 4, 
2013). The reference guidance documents clearly define the study, number of subjects, data points needed for the 
analysis and handling of missing data or data that is removed from the analysis. This is achieved through a 
minimum of [ADDRESS_713799] and Reference values equally distributed over the specified SpO 2 
accuracy range (70 -100%) of the device under test. The data will be collected on a minimum of 10 healthy adult 
volunteer subjects who range in age, gender and skin tone with 2 of the s ubjects or 15% of the subject pool 
(whichever is larger) having deep skin pi[INVESTIGATOR_545490]. An Accuracy Root Mean Square (A RMS) calculation is 
used as a means to define the SpO [ADDRESS_713800] for determination of plateau 
levels and safety. Additionally, the oxygen saturation values (SpO 2) of a control oximeter will be used to assess the 
stability of the pla teaus for data collection. There are no provisions for an interim analysis. For the v alidation , the 
Stable Plateaus
65707580859095100
1357911131517192123
# of PointsSaO2 Ranges
 
 
Clinimark  
[ADDRESS_713801]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713802] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   20   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
SpO [ADDRESS_713803]  measurement of blood SaO 2 by a  
CO-Oximet er. Data analysis & demographics will be presented in the final report.  
 
Control oximeter stability criteria  
The control oximeter will provide the real time oxygen saturation level of the subject for determination of 
plateau levels and safety.  
The data points are considered u nstable and removed from the analysis:  
• if the Control Oximeter SpO 2 value varies by >2% during the simulated draw time  
• if the combined minimum and maximum deviations of the Control Oximeter SpO 2 value are > 3% during 
the review period of [ADDRESS_713804] to 
removal. The functional oxygen saturation value will be used for the b asis of comparison to SpO 2 value 
collected from the pulse oximeter. Draws with COHb values >3% or MetHb values >2% or tHb <10 g/dl will be 
excluded from the data. When multiple CO -Oximeters are used, data that presents outliers from the other CO -
Oximeters will be removed from the average of all CO -Oximeters. Outliers are defined as a CO -Oximeter SO 2 
values (functional oxygen saturation) that are >2% from the other CO -Oximeter’s values. In the case where 2 
CO-Oximeters are used, the data will be averaged unl ess the difference between the 2 CO -Oximeters is >2%. 
When the 2 CO -Oximeters deviate by >2%, the tHb, COHb, MetHb values will be reviewed for consistency to 
the other draws for this subject. If those values are found to be similar in readings for a given subject, then it is 
determined that the true reference value is unstable and the point will be removed from the analysis. If the 
finding is that one of the CO -Oximeter’s has an SO [ADDRESS_713805], then the offending CO -Oximeter value will not be used and the other 1 CO -
Oximeter SO 2 value will be used as the reference for comparison.  
 
Draws with CO -Oximeter data that are < 67% will be removed.  
  
Test SpO 2 Data Removal:  
• The test S pO 2 values recorded as 100% will be removed prior to the analysis.  
• Zero values  or no reading  (drop outs in  SpO 2 or pulse rate) will be excluded from the calculations for SpO 2. 
 
A rationale will be provided for any data that is excluded from the data analysis .  
 
The data will be plotted and analyzed through the following statistics, using the Reference CO-Oximetry S aO2 
value for the x value and the Test Devices SpO 2 value for the y value.  
 
Ref = Reference CO-Oximetry S aO2 
DUT = Device Under test SpO 2  
 
SpO 2 accuracy will be evaluated for root -mean -square (rms) difference between the DUT and the reference for 
the specified SpO 2 ranges (70 -100%) and by [CONTACT_7535] 2 decade (90 -100%, 80<90%, 70 -<80%). The number of data 
points will be included for each statistic.  
 
ni i
Armsn
if DUT−
==12) Re (
 
 
 
 
Clinimark  
[ADDRESS_713806]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713807] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   21   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
The average difference is calculated to show the bias of the device under test as compared to the reference. 
The bias is calculated for the specified SpO 2 ranges (70 -100%) and by [CONTACT_125938] (90 -100%, 80<90%, 70 -<80%).  
 
nBiasn
ii i f DUT) (
1Re
=−
=
 
 
A least squares line (slope and intercept) will be generated for the overall range.  
The minimum and maximum deviations will be calculated from the reference.  
 
Bland -Altman graphical plots, error (SpO 2 – SaO 2) versus average SaO 2 +SpO 2 will be generated with linear 
regression fit, mean, and upper 95% and lower 95% limits of agreement according to Section 3 of “Agreement 
Between Methods Of Measurement With Multiple Observations Per Individual“  by [CONTACT_136187] [ADDRESS_713808] subjects will be color coded in the Bland -Altman 
graphical plot.  
 
Values for the population mean bias (μ 0), between -subject variance (σ μ2) and within -subject variance (σ2) will 
be calculated according to Section 3 of “Agreement Between Methods Of Measurement With Multiple 
Observations Per Individual” by [CONTACT_136187] [ADDRESS_713809] subjects will be color coded in the Bland -Altman graphical plot.  
 
Error plots (i.e ., SaO 2 versus (SpO 2-SaO 2) for both individual test subjects and all subjects pooled) will be 
generated.  
 
Additionally,  a scatter plot of the subject pool will be generated.  
 
Test device outliers with a value >5% difference from the Reference CO -Oximeter will be discussed in the Final 
report per the FDA Guidance document for Pulse Oximeters.   Test data>3% will be noted.  
 
Pass / Fail Criteria  
The statistical results of the data will be reviewed for t he following pass/fail criteria:  
• SpO 2 Accuracy for the range of 70 -100%,  ≤ 3 (A RMS) is a Pass.  
  
Deviations from the Statistical Plan  
Any deviations from this statistical plan will be described and justified in the final report.  
 
Investigational Review Board (IRB)/Independent Ethics Committee (IEC)  
Prior to the start of subject enrollment, the sponsor/investigator will be responsible for obtaining approval from 
the authorized IRB/IEC for the institution at which the proposed clini cal investigation is to be conducted. Written 
approval from the IRB/IEC should specifically refer to the investigator, the protocol title and date, and subject 
informed consent date.  
 
Written IRB/IEC approval and any conditions of approval imposed by [CONTACT_941] I RB/IEC will be obtained by [CONTACT_103]/investigator.  
 
Protocol amendments must also undergo IRB/IEC review and approval at each clinical site. The written approval 
from the IRB/IEC for the amendment should specifically refer to the investigator, the protoc ol version number and 
title, and any amendment numbers that are applicable.  
 
 
 
Clinimark  
[ADDRESS_713810]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713811] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   22   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Monitoring Arrangements  
Owlet Baby [CONTACT_545492], Inc.  or Clinimark personnel  (Louisville, C O, [LOCATION_003] ) will provide all monitoring. The Monitor shall be 
responsible for maintaining a record of the findings, conclusions, and actions taken for the results of monitoring 
the study ensuring that:  
 
The monitoring requirements for an NSR device study is identified in 21 CFR 812.2(b) Abbreviated requirements. 
For monitoring an NSR device inves tigation, the requirement is to comply with [ADDRESS_713812] to 
monitoring investigations: (a) Securing Compliance, (b) Unanticipated adverse device effects, (c) Resumption of 
terminated studies  
 
• Compliance to the signed agreement between the Investigator and sponsor  
• The study follows the protocol and any amendments that apply  
• Compliance to any conditions of the approval imposed by [CONTACT_164287]:  
• The conditions for the study continue to be acceptable  
• Accurate, complete, and curr ent records are maintained and required reports are written  
• Any adverse effects are documented and reported to the Sponsor and IRB as appropriate  
• Monitor activities may include for example:  performing source data verification and requesting corrections to  
feedback forms where potential inconsistencies or missing values are identified.  
• Findings of non -compliance or required modifications are reviewed with the investigator and the Sponsor, and 
is presented in a written report to both  
• Providing a Monitoring Report at the end of the Clinical Investigation  
 
Monitoring Plan  
1) Informed Consent  
• Verify that the consent form was signed prior to any study procedures being conducted  
• Verify that the staff conducting the consent is listed for approval on the Delegation o f Authority Log  
• Ensure that the consent process is documented.  
2) Subject Eligibility  
• Verify that the subject meets the inclusion criteria and none of the exclusion criteria.  
3) Baseline Data  
• Verify demographic information with the health assessment form  
• Check that informed consent time and date is prior to start of the procedure  
4) Verify all CRFs are completed  
5) Adverse Events  
• Verify that Adverse Events and Serious Adverse Events / UADEs are being reported accordingly to the IRB 
and Sponsor in the required ti meframe.  
6) Protocol Deviations  
• Verity that Protocol Deviations are being reported accordingly to the IRB and Sponsor in the required 
timeframe  
7) Electronic Data Review  
• Verify that the filename [CONTACT_545507].  
8) Ensure the Trial Master File is complete.  
 
Data and Quality Management / Confidentiality  
A checklist will be maintained identifying the contents of the Trial Master File / Project folder PFC# [ADDRESS_713813]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713814] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   23   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
The subject’ s name [CONTACT_523190], Health Assessment Form, Subject 
Follow -up, Clinician Subject Flow Sheet form and a subject participation list. The data collection form will only use 
a subject number and initials for the day o f the test along with subject demographics. A name [CONTACT_545508].  
 
Records identifying the subject’s name [CONTACT_7637] a secured location with either a locked file or locked door.  
Access to these files will be on a limit ed basis. Potential reviewers of this information include: Clinimark 
representatives collecting the information and conducting the study, Medical Director for Clinimark, the U.S. Food 
and Drug Administration (FDA), Department of Health and Human Services ( DHHS) agencies, Governmental 
agencies in other countries, Salus Independent  Review Board and representatives of the Sponsor. This group may 
use the information to conduct independent audits and reviews to verify compliance of the regulatory 
requirements fo r these studies but not copy the information.  
 
Data files stored electronically will be associated with a subject based off of subject #, date and by [CONTACT_348562]. The original device electronic data files will be preserv ed in its original form. 
Data analysis will be performed as a separate electronic file.   
 
Data files, data collection records with subject demographics and subject number may be additionally copi[INVESTIGATOR_530], 
(after de -identification, if applicable) reviewed and su pplied to the commercial sponsor for the study or 
Contractors associated with Clinimark for data analysis purposes.  
 
All study records will be stored for at least [ADDRESS_713815] cancellation. The 
investigator will notify  sponsor prior to destruction of study records.  Other storage arrangements may be 
executed per contractual agreement between the sponsor and the investigator.  
 
Records - Study Documentation / Case Report Forms  
SpO2 Accuracy Comparison of Smart Sock V. 2  SpO2 to Arterial Blood CO -Oximetry  
Clinimark Study ID# PR [ADDRESS_713816] Documents  
Provided as separate documents to this protocol : 
• Informed Consent form (IRB approved)  
• Health Assessment Form ( Clinimark Control # F2000 -001-001 Rev 13  or current revision ) 
• Arterial Puncture Wrist Care Instructions Rev [ADDRESS_713817] Documents : 
• CRF2017 -263 – Case Report  Forms  
• Clinimark Control# F2000 -001-003 – Subject follow -up form  
• Clinimark Control # F2000 -001-005 – Clinician: Subject Flow Sheet form  
• Electronic Files – electronic data collected from the pulse oximetry system s 
 
Data Collection Forms / Case Report Forms  
To ensure the quality and integrity of the data, it is the  responsibility of the Investigator(s) or designee to complete 
the Case Report Forms (CRFs) for each subject who is enrolled to participate in this study.  
In some cases,  the data collection forms will also be the source document for some information that is not directly 
collected in the Health Assessment Form. The following information will be recorded on the site’s data collection 
forms ( CRF): 
• Study date, Subject ID#, Su bject Initials, and Relevant Subject Demographics, Associated Electronic 
Filename(s)  
• Evidence that informed consent was signed and dated prior to the subject participating in the study  
 
 
Clinimark  
[ADDRESS_713818]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713819] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   24   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
• Information for Subject Inclusion or Exclusion to the study  
• Equipment c alibration and communication check out  
• Device usage / sensor placement on the subject  
• Baseline SpO 2 and pulse rate  
• Annotations on data point markers, stability, and other observations used in the data analysis  
• Protocol deviation reporting  (only if needed)  
• Adverse Events reporting  (only if needed)  
• Study termination  
• Subject Follow up form   
 
A black or blue pen will be used to record data on the data collection forms. Recorded information should be 
legible and completed. Erroneous entries sh ould be crossed out, corrected with the change, initialed and dated by 
[CONTACT_114654]. The Investigator(s) or designee will sign and date at indicated places on each 
page of the data collection form. The Protocol Deviations Reporting can be signed and dated by [CONTACT_348563], otherwise the Sub -Investigator or Investigator should review, sign and date. The Adverse 
Events Reporting should be signed and dated by [CONTACT_164289] a Sub -Investigator or Investig ator. The Principal 
Investigator [INVESTIGATOR_348549], sign and date all serious adverse events.  The Investigator or designee will provide a 
final signature [CONTACT_164306] a thorough inspection of all subject data has been performed and will thereby [CONTACT_164290]. The Investigator’s Certification Statement will disclose the overall documentation, study 
oversight and certification of the study.   
  
Trial Master File Documents  
• Clinimark Control # B3000 -000-003 – Adverse Events and Protocol De viation Reporting System  
• Clinimark Control # F2000 -001-029 - Device Deficiency Form  
• Clinimark Control # F2000 -001-016 - Device Accountability Form  
• Clinimark Control # F2000 -001-015 - Delegation of Authority  
• Clinimark Control # F2000 -001-[ADDRESS_713820] Disclosure  
• Clinimark Control # F2000 -001-022 – Investigator’s Certification Statement  
• Clinimark Control # F2000 -001-[ADDRESS_713821] Enrollment Log  
• Clinimark Control # F2000 -001-027 - Site Personnel Training Log  
• Clinimark Control # F2000 -001-033 - Site Visit/ Monitoring Log  
• Clinimark Control # F2000 -001-034 - Data Clarification Form  
• Protocol Deviation Log  
• Adverse Events Log  
• Communications  
Current revision of documents apply.  
 
Amendments to the Clinical Investigation Plan  
Owlet Baby [CONTACT_545492], Inc.  or site may need to make protocol changes during the study. Such amendments will be 
documented, reviewed and changes will be submitted to Owlet Baby [CONTACT_545492], Inc.  for first approval, then to the IRB 
for approval. Owlet Baby [CONTACT_545492], Inc.  and site will  make a decision regarding the continuation of subject enrollment 
during this period. The site may proceed with the amendment upon receipt of IRB approval.  
 
Deviations from the Clinical Investigation Plan  
Investigators are not allowed to deviate from the Clinical Investigation Plan  (CIP) except under emergency 
circumstances. Deviations from the CIP to protect the rights, safety and well -being of human subjects may proceed 
without prior approval of the spons or and the IRB. Such deviations shall be documented and reported to the 
sponsor and the IRB as soon as possible but within [ADDRESS_713822]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713823] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   25   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Deviations that significantly affect the safety, efficacy, integrity, or conduct  of the study must be reported to the 
Sponsor within [ADDRESS_713824] of the study will be doc umented in the case 
report forms, regulatory binder Protocol Deviation Log as appropriate.  
  
Device Accountability  
A Device Accountability Log will be maintained for the sponsor’s equipment documenting date of receipt, 
description of device (including mode l#, lot#, serial number or unique code, and quantity)  and date of return for 
used and unused product.  Device usage will be recorded in the Case Report Form for each individual subject.  
 
Packaging and Labeling  
Research conducted for this study will utilize investigational devices and devices cleared through the 510k 
regulatory process. The Sponsor is responsible for packaging and labelling of the device for delivery to the study 
site. FDA cleared devices do not require special labelling. Investigational devi ces or its immediate package shall 
bear a label with the following information: name [CONTACT_164307], packager, or distributor, the 
quantity of contents, if appropriate, and the following statement:  
“CAUTION - Investigational device. Limited  by [CONTACT_4496] (or [LOCATION_002]) law to investigational use.”  
 
The label or other labeling shall describe all relevant contraindications, hazards, adverse effects, interfering 
substances or devices, warnings, and precautions.  
 
It is the investigator’s respon sibility to ensure the appropriate labelling is visible and remains intact throughout the 
life of the study.  
 
The Instructions for Use (IFUs) are provided as separate documents from this protocol.  
 
Storage and Accountability  
The site will store the investi gational product. The storage area should be locked/secure with access limited only to 
approved study staff.  
 
The site will record/track use of the investigational device by [CONTACT_20908]. Documentation should verify that 
the device use was in accordan ce with the approved protocol. Equipment Document in the Case Report Form shall 
provide documentation of the devices used on the study participant(s).  
 
Statement of Compliance  
The study will be conducted in accordance with the Declaration of Helsinki, 21 CFR 50, and 21 CFR 812  for non -
significant risk device study investigations . The study will not commence until the approval has been received from 
the IRB.  
 
Reference Documents  
• IRB Approved Informed Consent for Study Title: Accuracy Comparison of Smart Sock V. 2  SpO2 to Arterial 
Blood CO -Oximetry  PR 2017 -263 
• ISO [ADDRESS_713825] edition 2011 -04-01, applicable sections, Clause 50 and Annex EE.3 Medical electrical 
equipment — Part 2 -61: Particular requirements for basic safety  and essential performance of pulse 
oximeter equipment  
• FDA Guidance Document for Pulse Oximeters, March 4, 2013  
• World Medical Association Declaration Of Helsinki, Ethical Principles for Medical Research Involving 
Human Subjects  
 
 
Clinimark  
[ADDRESS_713826]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713827] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   26   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
• 2011 -02-01 Clinical investig ation of medical devices for human subjects — Good clinical practice  
• Clinimark Adverse Events Reporting Document B3000 -000-003 (current revision)  
 
Informed Consent Process  
• The Principal Investigator [INVESTIGATOR_022] / her designee conducts the informed consent proce ss 
• Verify that the subject acknowledges ability to read English  
• Instruct the subject to ask questions at any time during this process, especially about things they do not 
understand.  
• Allow subject ample time to read the entire form and ask questions.  
• Give a thorough description of the study and the subject’s involvement – especially explain that they may 
withdraw from the study at any time.  
• After the subject has read the form ask if they understand everything  
• Ask if they would like to take part in the study  and if so explain that they may sign and date the form.  
• Once the subject has signed and dated the informed consent, the principal investigator [INVESTIGATOR_545491].  
• Give a copy of the informed consent to the subject.  
• No procedure may be performed before the informed consent is signed by [CONTACT_545504] a device without obtaining informed consent, the investigator shall report such use to the 
sponsor and the reviewing IRB within [ADDRESS_713828].  
The Clinima rk Desaturation Fixture does not require maintenance. At the start of each day of the study, the 
fixture is calibrated with calibration gas. A secondary monitor independent of the fixture is used to measure 
and document the FiO 2 delivered at 3 levels. The measurement is expected to be within ± 1 of the FiO 2 setting 
for the fixture.  
 
There are three steps used to ensure safe gas mixture delivery. The fixture implores continuous monitoring of 
gas flow and mixtures. Should the measurements drop below a predete rmined level either the primary O 2 
and/or N [ADDRESS_713829]’s well -being during the test.  
    
The subject will review and sign the informed consent following a discussion of the test procedure and when 
all questions regarding the study have been answ ered and prior to start of any study procedures. The subject 
will complete the health assessment questionnaire and disclose any pertinent issues that may affect his/her 
health during the test. The subject may withdraw from the study at any time. The subjec t may be withdrawn 
per the Procedure section below.   
 
A clinician will be present to monitor the subject at all times. Safety monitoring includes, SpO 2, pulse rate, 
relevant information on ECG rhythm, FiO 2, EtCO 2, respi[INVESTIGATOR_1487], direct observation and communication with 
the subject.  
 
 
 
Clinimark  
[ADDRESS_713830]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713831] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   27   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Adverse Event Definitions  
The definitions for adverse event, adverse device effect, serious adverse event, serious adverse device effect, 
unanticipated adverse device effect, and their classifications are provided below (I SO [ZIP_CODE], 21 CFR 812.3).  
• Adverse Device Effect (ADE):  Adverse event related to the use of an investigational medical device 
resulting from insufficiencies or inadequacies in the instructions for use, the deployment, installation, 
the operation, or any malf unction of the investigational medical device or from error use.  
• Adverse Event (AE): Any untoward medical occurrence, unintended disease or injury or any untoward 
clinical signs (including an abnormal laboratory finding) in subjects, users or other persons  whether or 
not related to the investigational medical device or investigational procedure  
• Anticipated Serious Adverse Device Effects (ASADE):  ASADE is an effect which by [CONTACT_5942], 
incidence, severity or outcome has been identified in the risk analysis r eport.  
• Mild:  a mild adverse event is one in which the subject is aware of the event, but it is easily tolerated 
without intervention.  
• Moderate:  a moderate adverse event is one that causes sufficient discomfort to interfere with usual 
activities.  
• Serious Adverse Device Effect (SADE): adverse device effect that has resulted in any of the 
consequences characteristic of a serious adverse event  
• Seriou s Adverse Event (SAE):  a serious adverse event is an adverse event that results in death, 
inpatient hospi[INVESTIGATOR_059], severe or permanent disability, a life threatening illness or injury, fetal 
distress, fetal death, a congenital abnormality, a birth defect , or medical or surgical intervention to 
prevent permanent impairment to body or structure.  
• Severe:  a severe adverse event is one that results in the inability to perform usual activities.  
• Unanticipated Adverse Device Effect (UADE):  serious adverse device  effect which by [CONTACT_5942], 
incidence, severity or outcome has not been identified in the current version of the risk analysis 
report.  
 
Management of Adverse Event Reporting  
Should the subject experience an adverse or non -typi[INVESTIGATOR_164272], assessment of the situation is first initiated and a 
determination will be made of appropriate actions. The Medical Director and Principle Investigator will be 
contact[CONTACT_264760]. Adverse Events are reported through standard Clinimark Procedures, IRB requirements 
and per Owlet Baby [CONTACT_545492], Inc. ’s SOPs.   
 
Records of Adverse events will be recorded in the Case Report Form  
The following information will be obtained:  
• Type of effect (ADE, AE. ASADE, SADE, SAE, UADE)  
• Date of onset and resolution  
• Intensity (mild, moderate, sev ere) 
• Serious (yes/no)  
• Relationship to device (unknown, not related, possibly related, probably related, definitely related)  
• Anticipated (yes/no)  
• Treatment given and / or action taken (procedure stopped, withdrawn from study, no action)  
 
 
 
Reporting of Serious Adverse Events and / or UADE  
All SAE’s, SADE, ASADE and UADE will be reported in writing to the Principal Investigator, Medical Director, 
Sponsor and IRB within [ADDRESS_713832]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713833] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   28   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
If the event resulted in death of a su bject, the event shall be reported to the Principal Investigator, Medical 
Director, Sponsor and IRB within 24hrs of knowledge of the event.  
 
Sponsor Records and Reports  
Records 21 CFR 812.140 (b) 4,5  
The following records shall be consolidated in one location and available for FDA inspection and copying:  
• The name [CONTACT_29774];  
• A brief explanation of why the device is not a significant risk dev ice:  
• The name [CONTACT_29775]:  
• The name [CONTACT_29776]:  
• A statement of the extent to which the good manufacturing practice regulation in part 820 will 
be followed in manufacturing the device;  and  
• Any other information required by [CONTACT_8415].  
• Records concerning adverse device effects (whether anticipated or unanticipated) and 
complaints   
 
Reporting 21 CFR 812.150 (b) 1,2,3,5,6,7,8,9,10:  
The sponsor shall prepare and submit the following complete , accurate, and timely reports.  
 
Unanticipated Adverse Device Effect  
A sponsor shall immediately conduct an evaluation of an unanticipated adverse device effect. The results of 
such evaluation shall be reported to the FDA, IRB and participating investigators within [ADDRESS_713834] yearly.  
 
Recall and device  
The sponsor shall notify FDA and all reviewing IRB's of any request that an investigator return, repair, or 
otherwise dispose of any units of a device. Such notice shall occur within [ADDRESS_713835] was made.  
 
Final Report  
The sponsor shall submit a final report to the IRB with 6 months after termination or completion of the 
investigation.  
 
Informed consent  
The sponsor shall subm it to FDA a copy of any report by [CONTACT_348565] (a)(5) of this section 
of use of a device without obtaining informed consent, within 5 working days of receipt of notice of such use.  
 
Significant risk device determinations – (does not app ly to NSR studies)  
 
 
Clinimark  
[ADDRESS_713836]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713837] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   29   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
If an IRB determines that a device is a significant risk device, and the sponsor had proposed that the IRB 
consider the device not to be a significant risk device, the sponsor shall submit to FDA a report of the IRB's 
determination withi n [ADDRESS_713838] learns of the IRB's determination.  
 
Other  
A sponsor shall, upon request by a reviewing IRB or FDA, provide accurate, complete, and current information 
about any aspect of the investigation.  
 
Investigators Records and Reporting  
Records 21 CFR 812.140 (a)(3)(i)  
The investigator maintains records of each subject’s case history and exposure to the device and supporting 
data including signed and dated consent forms, health assessment form, and pro gress notes during the study. 
Records should show evidence that informed consent was signed and dated prior to the subject participating 
in the study.  
 
Reports 21 CFR 812.150 (a) 1,2,5,7  
The investigator shall prepare and submit the following complete, ac curate, and timely reports:  
 
Unanticipated adverse device effects  
The investigator shall submit to the sponsor and to the reviewing IRB a report of any unanticipated adverse 
device effect occurring during an investigation as soon as possible, but in no event later than [ADDRESS_713839].  
 
Withdrawal of IRB approval  
The investigator shall report to the sponsor, within 5 working days, a withdrawal of approval by [CONTACT_545505]'s part of an investigation.  
 
Informed consent  
If an investigator uses a devi ce without obtaining informed consent, the investigator shall report such use to 
the sponsor and the reviewing IRB within [ADDRESS_713840] completed the study procedure without incide nce or any adverse events.  
 
Participation in the study may also be stopped at any time by [CONTACT_458] [INVESTIGATOR_164273] -investigators 
or sponsor.  
• The subject’s failure to cooperate fully (as determined by [CONTACT_545506]) with the 
required conduct of this study.  
• The subject’s development of an illness as determined by [CONTACT_348568].  
 
 
Clinimark  
[ADDRESS_713841]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:  SpO2 Accuracy Comparison of Smart Sock V. [ADDRESS_713842] udy ID# PR 2017 -263 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2017 -263 
SHEET   30   of   31 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
• A determination by a Clinimark representative (in his or her sole discretion), for whatever cause, tha t the 
study should be discontinued.  
• A determination by [CONTACT_456] (in his or her sole discretion), for whatever cause, that the study should be 
discontinued  
 
The collection of data for study subjects will cease in the following cases:  
• Subject completes a ll study requirements  
• Subject withdraws consent  
• Investigator’s decision that it is in subject’s best interest to be discontinued from the study  
• Subject death  
• Adverse event other than death requiring withdrawal of the subject from the study  
• Determination that the subject was ineligible for the study.  
 
There will not be any follow -up procedures for withdrawn or discontinued subjects required, unless a follow -up is 
required a t the Investigator’s discretion . 
 
Consideration for early termination or suspension of the investigation is tied to unanticipated equipment failure or 
a decision by [CONTACT_348569]. Both  Owlet Baby [CONTACT_545492], Inc.  and Clinimark reserve the right to discontinue the 
study at any time for administrative or other reasons. Wri tten notice of study termination will be submitted to the 
investigator in advance of such termination. Termination of a specific site can occur because of, but not limited to, 
inadequate data collection, low subject enrollment, or non -compliance with the p rotocol or other research 
requirements.  
 
Early termination results when the study is  closed prior to the end of the study. A study suspension is  a temporary 
postponement of the study activities related to enrollment. Both are possible for the study.  
 
If the study is terminated or suspended, no additional enrollment will be allowed unless otherwise informed by [CONTACT_103]. The current subjects will be followed according to the protocol.  
 
If the study is terminated prematurely or suspended by [CONTACT_456]/in vestigator, the sponsor /investigator will 
promptly inform the regulatory authorities (if required) of the termination and the reason(s). IRB/IECs will also be 
promptly informed and provided with the reason(s) for termination or suspension by [CONTACT_456]/ investigator. 
The investigator will promptly inform the subjects and assure appropriate follow -up for the subject.  
 
If the investigator (or IRB/IEC) terminates or suspends the investigation the investigator will promptly inform the 
institution (if required ) and the IRB/IEC, and provide a detailed written explanation of the termination or 
suspension. The investigator will promptly inform the subjects and assure appropriate therapy and follow -up for 
the subjects. The sponsor will inform the regulatory authori ties (if required).  
 
Withdrawal of IRB approval shall be reported to the sponsor by [CONTACT_19452] 2 working days.  
 
In case of early termination of the study, all study subjects should be followed until the resolution of any pending 
adverse event( s). 
 
Publication Policy  
The results of this investigation will not be submitted for publication.  